burosumab 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
human origin	5282	1610833-03-8

Description:

Molecule	Description
Molfile Synonyms: burosumab KRN23 burosumab-twza crysvita	X-linked hypophosphatemia is caused by excess fibroblast growth factor 23 (FGF23) which suppresses renal tubular phosphate reabsorption and the renal production of 1,25 dihydroxy vitamin D. Burosumab-twza binds to and inhibits the biological activity of FGF23 restoring renal phosphate reabsorption and increasing the serum concentration of 1,25 dihydroxy vitamin D. Molecular weight: Formula: CLOGP: LIPINSKI: None HAC: None HDO: None TPSA: ALOGS: ROTB: None

Molecule

Description

Molfile

Synonyms:

burosumab
KRN23
burosumab-twza
crysvita

X-linked hypophosphatemia is caused by excess fibroblast growth factor 23 (FGF23) which suppresses renal tubular phosphate reabsorption and the renal production of 1,25 dihydroxy vitamin D. Burosumab-twza binds to and inhibits the biological activity of FGF23 restoring renal phosphate reabsorption and increasing the serum concentration of 1,25 dihydroxy vitamin D.

Molecular weight:
Formula:
CLOGP:
LIPINSKI: None
HAC: None
HDO: None
TPSA:
ALOGS:
ROTB: None

Drug dosage:

Dose	Unit	Route
2.50	mg	P

ADMET properties:

None

Approvals:

Date	Agency	Company
Feb. 2, 2018	EMA	KYOWA KIRIN LIMITED
April 17, 2018	FDA	ULTRAGENYX PHARM INC
Sept. 20, 2019	PMDA	Kyowa Kirin Co., Ltd.

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	M05BX05	MUSCULO-SKELETAL SYSTEM DRUGS FOR TREATMENT OF BONE DISEASES DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION Other drugs affecting bone structure and mineralization

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Osteomalacia	indication	4598005	DOID:10573
Familial x-linked hypophosphatemic vitamin D refractory rickets	indication	82236004
Renal impairment	contraindication	236423003

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Fibroblast growth factor 23	Secreted	Q9GZV9	FGF23_HUMAN	ANTIBODY BINDING				UNKNOWN	DRUG LABEL

External reference:

ID	Source
G9WJT6RD29	UNII
C4301607	UMLSCUI
CHEMBL3707326	ChEMBL_ID
DB14012	DRUGBANK_ID
D10913	KEGG_DRUG
10301	INN_ID
9292	IUPHAR_LIGAND_ID
276299	MMSL
34098	MMSL
34099	MMSL
d08781	MMSL
017502	NDDF
772032008	SNOMEDCT_US
772041003	SNOMEDCT_US
4037505	VANDF
4037506	VANDF
2043854	RXNORM
C000601956	MESH_SUPPLEMENTAL_RECORD_UI

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
CRYSVITA	HUMAN PRESCRIPTION DRUG LABEL	1	42747-102	INJECTION	10 mg	SUBCUTANEOUS	BLA	31 sections
CRYSVITA	HUMAN PRESCRIPTION DRUG LABEL	1	42747-203	INJECTION	20 mg	SUBCUTANEOUS	BLA	31 sections
CRYSVITA	HUMAN PRESCRIPTION DRUG LABEL	1	42747-304	INJECTION	30 mg	SUBCUTANEOUS	BLA	31 sections
CRYSVITA	HUMAN PRESCRIPTION DRUG LABEL	1	69794-102	INJECTION	10 mg	SUBCUTANEOUS	BLA	32 sections
CRYSVITA	HUMAN PRESCRIPTION DRUG LABEL	1	69794-102	INJECTION	10 mg	SUBCUTANEOUS	BLA	32 sections
CRYSVITA	HUMAN PRESCRIPTION DRUG LABEL	1	69794-203	INJECTION	20 mg	SUBCUTANEOUS	BLA	32 sections
CRYSVITA	HUMAN PRESCRIPTION DRUG LABEL	1	69794-203	INJECTION	20 mg	SUBCUTANEOUS	BLA	32 sections
CRYSVITA	HUMAN PRESCRIPTION DRUG LABEL	1	69794-304	INJECTION	30 mg	SUBCUTANEOUS	BLA	32 sections
CRYSVITA	HUMAN PRESCRIPTION DRUG LABEL	1	69794-304	INJECTION	30 mg	SUBCUTANEOUS	BLA	32 sections